Update Note
Partnering dependent - Q3 review
Klas Palin
2026-11-13
15:03 CET
As expected, the Q3 figures contained no major surprises but underscored the company’s limited financial runway. While recent portfolio progress has led to the initiation of partnering discussions, we do not expect any material near-term news flow. However, we believe successful transactions could unlock significant value and reduce financing risk. Still, given the increased financing risk, we have widened our fair value range to SEK10–27 per share (SEK21–27) to better capture the current elevated risk profile.
Costs down in Q3. Opex was SEK6.0m in Q3, down SEK2.4m Q/Q, reflecting seasonality and lower clinical activity. In the absence of income, operating cash flow was slightly more negative at SEK-6.8m. Cash and short-term investments stood at SEK16.8m at the end of Q3. Management now estimates that existing resources are sufficient to fund operations through Q2 2027, broadly in line with our previous assumption.
Partnering initiated. As we have noted previously, the pipeline has made significant progress in recent months. However, Vivesto lacks the financial and internal resources to advance the programmes independently and has therefore initiated partnering discussions across both its veterinary and human health portfolios. While we view partnering as the most likely path forward, such discussions typically take time and offer limited external visibility, leaving both the timing and outcome uncertain.
Estimate changes. We lower our cost assumptions somewhat following the Q3 outcome and updated guidance on cash-burn, and therefore raise our 2026–27 EPS estimates by 3–7%.
Lower valuation. Given the uncertainty surrounding the long-term financing of the programmes, we widen our fair value range to SEK10–27 (SEK21–27) per share. The lower end reflects increased financing risk through a higher WACC assumption of 30%, while the upper end assumes supportive partnering outcomes.